Background Patients with renal-cell carcinoma who undergo nephrectomy have no options
for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting …

Background The first interim analysis of the KEYNOTE-564 study showed improved disease-free
survival with adjuvant pembrolizumab compared with placebo after surgery in patients …

Background Major depression is an important complication of cancer. However, reliable data
are lacking for the prevalence of depression in patients with cancer in different primary sites…

Background Depression has substantial effects on cancer patients' quality of life. Estimates
of its prevalence vary widely. We aimed to systematically review published studies to obtain …

Background Medical conditions are often complicated by major depression, with consequent
additional impairment of quality of life. We aimed to compare the effectiveness of an …

Background Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was
approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-…

Background The management of depression in patients with poor prognosis cancers, such
as lung cancer, creates specific challenges. We aimed to assess the efficacy of an integrated …

Background This was a first-in-human Phase 1/2 open-label dose-escalation study of the
novel checkpoint kinase 1 (Chk1) inhibitor SRA737. Methods Patients with advanced solid …

Objective The question of whether depression is associated with worse survival in people
with cancer remains unanswered because of methodological criticism of the published …

290 Background: The double-blind, multicenter, randomized KEYNOTE-564 study (NCT03142334)
is the first positive phase 3 study of adjuvant immunotherapy for patients (pts) with …